Introduction and study background. Julio Rosenstock, MD
Study design, statistical plan, and baseline characteristics. Mark Espeland, PhD
Metabolic and body weight outcomes. Steven E. Kahn, MB, ChB
Cardiovascular, mortality, and hospitalization outcomes. Nikolaus Marx, MD, FESC, FAHA
Adverse events and hypoglycemia analyses. Bernard Zinman, CM, MD
Clinical implications for the cardiologist and diabetologists. Darren K. McGuire, MD, MHSc, Bernard Zinman, CM, MD
Independent commentator. Matthew C. Riddle, MD
Final Remarks and acknowledgements. Julio Rosenstock, MD
The diabetes community is anxiously awaiting the results of this cardiovascular outcome trial. As the only active comparator trial, we are hoping to learn more about the use of a sulfonlyurea in high-risk patients when compared to a DPP-4 inhibitor.
This session is 2 hours long, but each second should be worth it. All of us who deal with people living with diabetes will gain from the expert opinions presented here. Using insulin, ensuring adherence, achieving weight loss, and managing diabetes burnout will figure in this session. The speakers will provide insight which will help translate current knowledge into effective clinical practice.
Friday June 7th, 11:30–12:30. Room S157, Moscone Center, San Francisco, California
Rationale and study design. Myrlene A. Staten, MD
Recruitment, retention, and baseline characteristics. Erin S. Leblanc, MD, MPH
Outcomes. Anastassios G. Pittas, MD, MS
The D2d trial is of particular interest due to a growing body of evidence which suggests that glucose and insulin metabolism may have farther-reaching effects on health and nutrition than previously thought. There now appears to be a greater understanding as to why so many patients with type 2 diabetes have vitamin D deficiency, and we need to determine if it's causative or as a result of insulin resistance.
Saturday 8 June: 8:00–10:00. Room S-203, Moscone Center, San Francisco, California
Are nutrition and diabetes education interventions effective in improving outcomes? Janice MacLeod, MA, RDN, CDE
What’s the best eating pattern for adults with diabetes? William S. Yancy, Jr., MD, MHS
What’s the role of weight loss in overweight/obese adults with diabetes? W. Timothy Garvey, MD
What’s the best approach for optimizing glycemic control?(macronutrients and insulindosing.) Ka Hei Karen Lau, MS, RD, LDN, CDE
What’s the role of nutrition in diabetes prevention? Christopher D. Gardner, PhD
Translation to practice.Kelly M. Rawlings, MS
Ever-changing – always evolving – nutritional recommendation are one of the cornerstones of diabetes management. Evolving evidence of the benefit of different dietary patterns will help us to guide our patients in the healthy lifestyle behavior.
PIONEER 6: Metabolic and safety outcomes. Ofri Mosenzon, MD, MSc
Summary. John B. Buse, MD, PhD
Independent commentary. Vivian Fonseca, MD
An exciting time for the GLP-1RA class with the introduction of the first oral preparation. The PIONEER program will provide safety and efficacy data across a broad range of patients as well as provide us with insight into the cardiovascular safety in the PIONEER 6 trial.
Friday 7 June, 14:00–16:00. Room S-157, Moscone Center, San Francisco, California
Evidence and mechanisms for paternal epigenetic regulation of developmental origins of health and disease. Elvira Isganaitis, MD, MPH
Obesity and bariatric surgery drive epigenetic variation of spermatozoa (human). Ida Donkin, MD, PhD
Preconception diet or exercise intervention in obese fathers normalizes sperm microRNA profile and metabolic syndrome in female offspring (mouse). Nicole O. McPherson, PhD
Paternal long-term exercise programs offspring for low energy expenditure and increased risk for obesity in mice. P. Darrel Neufer, PhD
Cold-induced epigenetic programming of the sperm enhances brown adipose tissue activity in the offspring (human and mouse). Christian Wolfrum, PhD
The session seems interesting for clinicians, educators and researchers. Findings discussed in talks at this symposium will stimulate us to view men as important contributors to the health of their offspring. A focus on pre-conception counselling in males should help us understand and address the epidemic of diabetes and other metabolic disease.
Top-line results for the REWIND trial have stated that superiority was achieved. We are keenly awaiting the full report to fully understand the benefit of a GLP-1RAs in a population of people without established cardiovascular disease. Unlike prior trials with GLP-1RAs the majority of this participants do not have atherosclerotic cardiovascular disease.
Following the publication of the pediatric medication and adult gastric banding studies, the RISE investigators will now present results showing whether early, intensive medication can preserve beta-cell function in adults with type 2 diabetes.
The REWIND investigators will report the cardiovascular safety of the weekly injectable glugacon-like peptide-1 receptor agonist dulaglutide in a lower-risk population than recruited to previous trials.
The cardiovascular safety results for oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, will be revealed by the PIONEER 6 investigators in the last session of the ADA programme.